Paul Tudor Jones’s NovoCure NVCR Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $4.08M | Buy |
269,027
+46,218
| +21% | +$699K | 0.01% | 1427 |
|
|
2026
Q1 | $2.43M | Sell |
222,809
-61,836
| -22% | -$772K | ﹤0.01% | 1708 |
|
|
2025
Q4 | $3.68M | Sell |
284,645
-321,425
| -53% | -$4.13M | 0.01% | 1358 |
|
|
2025
Q3 | $7.83M | Buy |
606,070
+354,216
| +141% | +$4.73M | 0.01% | 906 |
|
|
2025
Q2 | $4.48M | Buy |
251,854
+135,436
| +116% | +$2.36M | 0.01% | 1158 |
|
|
2025
Q1 | $2.07M | Buy |
+116,418
| New | +$2.64M | 0.01% | 1325 |
|
|
2024
Q4 | – | Sell |
-78,752
| Closed | -$1.23M | – | 3364 |
|
|
2024
Q3 | $1.23M | Sell |
78,752
-303,830
| -79% | -$5.51M | ﹤0.01% | 1499 |
|
|
2024
Q2 | $6.55M | Buy |
382,582
+17,161
| +5% | +$302K | 0.03% | 547 |
|
|
2024
Q1 | $5.71M | Buy |
365,421
+181,062
| +98% | +$2.66M | 0.04% | 553 |
|
|
2023
Q4 | $2.75M | Buy |
184,359
+100,140
| +119% | +$1.34M | 0.02% | 941 |
|
|
2023
Q3 | $1.36M | Buy |
84,219
+6,270
| +8% | +$181K | 0.01% | 1132 |
|
|
2023
Q2 | $3.23M | Buy |
77,949
+14,717
| +23% | +$914K | 0.04% | 642 |
|
|
2023
Q1 | $3.8M | Buy |
63,232
+36,377
| +135% | +$2.91M | 0.06% | 489 |
|
|
2022
Q4 | $1.97M | Buy |
+26,855
| New | +$2.02M | 0.04% | 642 |
|
|
2022
Q3 | – | Sell |
-42,073
| Closed | -$2.92M | – | 2582 |
|
|
2022
Q2 | $2.92M | Buy |
+42,073
| New | +$3.17M | 0.08% | 339 |
|
|
2022
Q1 | – | Sell |
-3,531
| Closed | -$265K | – | 2462 |
|
|
2021
Q4 | $265K | Buy |
+3,531
| New | +$354K | ﹤0.01% | 1927 |
|
|
2021
Q3 | – | Sell |
-5,298
| Closed | -$1.18M | – | 2694 |
|
|
2021
Q2 | $1.18M | Buy |
+5,298
| New | +$1.03M | 0.02% | 783 |
|
|
2021
Q1 | – | Sell |
-15,472
| Closed | -$2.68M | – | 1771 |
|
|
2020
Q4 | $2.68M | Buy |
+15,472
| New | +$2.12M | 0.08% | 315 |
|
|
2020
Q3 | – | Sell |
-34,795
| Closed | -$2.06M | – | 1476 |
|
|
2020
Q2 | $2.06M | Buy |
34,795
+31,266
| +886% | +$2.06M | 0.1% | 242 |
|
|
2020
Q1 | $238K | Sell |
3,529
-5,924
| -63% | -$468K | 0.02% | 767 |
|
|
2019
Q4 | $797K | Buy |
+9,453
| New | +$763K | 0.04% | 575 |
|
|
2019
Q3 | – | Sell |
-30,096
| Closed | -$1.9M | – | 1261 |
|
|
2019
Q2 | $1.9M | Sell |
30,096
-18,374
| -38% | -$931K | 0.05% | 345 |
|
|
2019
Q1 | $2.33M | Buy |
+48,470
| New | +$2.33M | 0.1% | 237 |
|
|
2016
Q3 | – | Sell |
-16,700
| Closed | -$195K | – | 1630 |
|
|
2016
Q2 | $195K | Buy |
+16,700
| New | +$209K | ﹤0.01% | 1414 |
|
Other funds holding NVCR
SCM
QCM
Paul Tudor Jones's NVCR Position: Q2 2026 in Review
Paul Tudor Jones increased its NovoCure (NVCR) stake by 21% in Q2 2026, buying an estimated $699K and bringing the position to 269,027 shares worth $4.08M. The position accounts for 0.01% of the portfolio, ranked #1427.
Paul Tudor Jones first reported a position in NVCR in Q2 2016 and has held it in 24 quarters since. The position peaked at $7.83M in Q3 2025. 215 funds tracked by Wall St. Rank hold NVCR as of Q2 2026.
- Paul Tudor Jones held 269,027 shares of NovoCure worth $4.08M as of Q2 2026.
- Paul Tudor Jones bought 46,218 NovoCure shares in Q2 2026, an estimated $699K.
- NovoCure made up 0.01% of Paul Tudor Jones's portfolio in Q2 2026, its #1427 holding.
- Paul Tudor Jones first reported a position in NovoCure in Q2 2016 and has held it in 24 quarters since.
- Paul Tudor Jones's NovoCure position peaked at $7.83M in Q3 2025.
- 215 funds tracked by Wall St. Rank held NovoCure as of Q2 2026.
Based on Tudor Investment Corp's 13F filing for Q2 2026, filed 14 Aug 2026.